Media Requests
Please send all media-related inquiries and interview requests to mediarelations@lls.org.
An LLS representative will respond as soon as possible.
Everyday Heroes Fight for a Cancer-Free Future
Rye Brook, NY (April 15, 2021) Every three minutes, one person in the U.S. is diagnosed with a blood cancer. But, The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, is making game-changing progress in changing this statistic. Today, LLS officially kicked off its 32nd annual Man & Woman of the Year® campaign — a multimillion-dollar nationwid...
FDA Approves Isatuximab for Relapsed/Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved isatuximab (Sarclisa) in combination with carfilzomib and dexamethasone to treat adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. This is the second FDA approval for multiple myeloma in 2021 alone and is promising news in the fight against myeloma. The FDA approval is based on data from a Phase 3 ...
New Report: Patients Pay the Price with Proliferation of Substandard Health Plans
WASHINGTON, D.C., March 25, 2021 – A new report published by 30 patient organizations shows the significant risks patients face when they enroll in non-compliant and substandard health insurance products, and details ways state and federal lawmakers can help protect these vulnerable consumers. The report, “Under-Covered: How ‘Insurance-Like’ Products Are Leaving Patients Exposed,” issued by a coalition r...
LLS Statement about UK Study on Vaccine Efficacy in Cancer Patients
Findings from the recent King’s College London study show that three weeks after one dose of the Pfizer vaccine, an antibody response was found in 39% of solid cancer patients and just 13% of people with blood cancer, compared to 95% in healthy individuals. There was a promising report that three out of five (60%) blood cancer patients studied had an immune response after the second dose, but there were n...
LLS Statement on Anti-Asian Violence and Discrimination
The Leukemia & Lymphoma Society condemns violence and discrimination against members of the Asian, Asian American, and Pacific Islander community, which has intensified because of the pandemic and misinformation about how COVID-19 spreads. As an organization committed to scientific research, advocacy, education, and support, we must fight injustice and racism with the same urgency as we fight blood cancers. We...
New Survey Reveals COVID-19 Vaccine Hesitancy Among Those with Cancer Diagnosis
RYE BROOK, N.Y., March 8, 2021 - A new survey of more than 6,500 U.S. blood cancer patients and survivors reveals that only half are very likely to get a COVID-19 vaccine while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston University Questrom School of Business and The Behaviouralist, a London-based research cons...
The Leukemia & Lymphoma Society Launches National Patient Registry to Answer Crucial COVID-19 Questions for Blood Cancer Patients
RYE BROOK, N.Y., Feb. 17, 2021 – The Leukemia & Lymphoma Society (LLS) announced today a collaboration with Ciitizen, a digital health technology startup, to collect data on the impact of COVID-19 and vaccination from people with a current or past diagnosis of blood cancer as part of a broader strategic partnership. The LLS National Patient Registry opened today to enroll all blood cancer patients, including th...
NEW DRUG APPROVAL EXPANDS OPTIONS FOR PATIENTS WITH TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA
Rye Brook, N.Y. (February 26, 2021) – The U.S. Food and Drug Administration (FDA) today announced approval of melphalan flufenamide, also known as melflufen (Pepaxto), in combination with dexamethasone for the treatment of adults with multiple myeloma whose disease has returned or worsened following prior treatment with four different classes of drugs. Today’s approval of melflufen was based on results fr...